Obesity Medicine 2024 - Tirzepatide Global Trials and Efficacy Insights (Recorded)

This session will inform HCPs on the tirzepatide molecule, the SURMOUNT global trial program for the treatment of obesity and overweight, and the safety and efficacy data disclosure for SURMOUNT-3 and SURMOUNT-4.

CME/CE Expiration Date: 4/26/27

*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.

 

 

 

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    The Obesity Medicine Association (OMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Obesity Medicine Association designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the commensurate amount with the extent of their participation in the activity.
Course opens: 
04/29/2024
Course expires: 
04/26/2027
Cost:
$25.00

Jamy Ard, MD 

Deborah B. Horn, DO MPH MFOMA

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    The Obesity Medicine Association (OMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Obesity Medicine Association designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the commensurate amount with the extent of their participation in the activity.

Price

Cost:
$25.00
Please login or register to take this course.

Required Hardware/software

For best user experience we recommend using a computer to complete this course.